Alexion takes option to acquire Caelum's amyloidosis program

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) purchased an equity stake in Caelum Biosciences Inc. (New York, N.Y.) and an obtained an option to acquire the company, which is developing a mAb to treat amyloid light-chain (AL) amyloidosis.

The deal gives Alexion a path to gain

Read the full 428 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE